Author Affiliations: CF and Airways Microbiology Research Group (Drs Elborn and Tunney); Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences (Dr Elborn); and School of Pharmacy (Dr Tunney), Queen's University Belfast, Belfast, United Kingdom.
Bronchiectasis is a common condition. Although the true prevalence is unknown, the prevalence in the United States has been estimated to range from 4 per 100 000 in young adults to nearly 300 per 100 000 in persons 75 years and older.1,2 Although bronchiectasis is a pathological description, it describes a group of conditions of somewhat diverse etiology that result in impairment of innate immunity and chronic infection, which in turn result in bronchial damage and dilation of the airways.3 In general, when referring to the condition, cystic fibrosis (CF) is excluded for practical rather than scientific reasons and the condition is frequently identified as non–cystic fibrosis bronchiectasis.
Elborn JS, Tunney MM. Macrolides and BronchiectasisClinical Benefit With a Resistance Price. JAMA. 2013;309(12):1295–1296. doi:10.1001/jama.2013.2780
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.